Benzo(a)pyrene (BP) is a carcinogenic polycyclic aromatic hydrocarbon found in heavily polluted air, cigarette smoke, and smoked foods. It is also a ubiquitous contaminant in food and water. Extensive studies from several laboratories have implicated a specific diol epoxide derivative of BP, 7,,8a-dihydroxy-9a,10a-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene (BPDE-I), as the major electrophilic, mutagenic, and carcinogenic metabolite of BP involved in covalent binding to DNA (1) . The complete structure and conformation of the adduct formed between BPDE-I and DNA in vitro is known. It results from binding of the C-10 position of BPDE-I to the 2-amino group of guanosine and is designated BPDE-I-dG (1, 2) . This adduct has been detected as the major DNA adduct found when a variety of human, bovine, and rodent cells are exposed to BP in culture (2) (3) (4) (5) .
Recently it has become possible to quantify carcinogen adducts on DNA by immunologic methods (6, 7) . Since the DNA does not have to be radiolabeled, these techniques can be used on human samples to screen for exposure to potential environmental carcinogens. Polyclonal rabbit antibodies (8) (9) (10) (11) (12) as well as monoclonal antibodies (13) (14) (15) (16) highly sensitive immunoassays has led to the detection of femtomole levels of carcinogens in pug quantities of DNA (17) (18) (19) (20) . With this level of sensitivity (better than one adduct per 107 nucleotides), it is now feasible to monitor human populations for exposure to certain carcinogens. Previously a rabbit antibody to BPDE-I-dG was generated in animals immunized with BPDE-Imodified DNA (12) . This antiserum has been used in an enzyme-linked immunosorbent assay (ELISA) to screen human samples for BP binding (21) . Low but detectable levels of BPDE-I-DNA adducts were seen in lung DNA samples from five lung cancer patients. We decided to develop a panel of monoclonal antibodies to BPDE-Imodified DNA because of their high specificity to a single antigenic determinant and the possibility of a permanent supply of antibodies from long-term cell cultures (22) .
Materials and Methods

Chemicals
± BPDE-I [7p,8a-dihydroxy-9a, 10a-epoxy-7,8,9, 10-tetrahydrobenzo(a)pyrene, also designated "anti"] and ± BPDE II [7,B,8a- 
Synthesis of Immunogens and Immunization
Calf thymus DNA was modified in vitro with BPDE-I to a level of 1% as described previously (23) and denatured before immunization. BPDE-I-G-BSA was prepared by periodate treatment of guanosine, followed by modification with BPDE-I then coupling to BSA. Details have been published (22 Sera from the immunized mice were also titered by this procedure. Various dilutions of the sera (100 ,uL) were added to sets of three wells, one blank, uncoated well, an unmodified DNA coated well, and one well coated with BPDE-I-DNA. Those animals showing the highest titer against modified DNA were selected for fusion. For the competitive assay, wells were coated with 5 ng denatured BPDE-I-DNA (0.54% modified). The hybridoma supernatant was diluted and mixed with an equal volume of the competitor before adding 0.1 mL of this mixture to the well. Further steps were as described above.
Isotype Determination
Hybridoma supernatant (0.1 mL of 1:500 dilution) was added to wells coated with 5 ng BPDE-I-DNA. After incubation, rabbit antisera specific for mouse IgGj, IgG2, IgM or kappa chains (1:500 dilution) were added for 1.5 hr. This step was followed by the addition of goat anti rabbit IgG-alkaline phosphatase (1:500) for 1.5 hr. The substrate was then added and the enzyme activity determined as described above.
Results
Immunization of mice with either BPDE-I-DNA complexed to methylated BSA or with BPDE-I-G-BSA led to the production of stable clones producing antibody specific for BPDE-I-DNA. A total of five clones have been isolated and characterized ( The antibody was used at a 1:10,000 dilution.
0.2 ng DNA or 3 fmole of bound BPDE-I. Competitive ELISAs were used to determine the sensitivity of the antibodies and to obtain additional information about their specificity. Figure 2 shows that antibody 5D11 differs in its reactivity with modified native and denatured DNA. With native DNA, 50% inhibition is at 180 fmole BPDE-I-dG adduct, while with denatured DNA it is at 19 fmole. The antibody is even less reactive with modified RNA (50% inhibition at 18,000 fmole). The highest sensitivity of the antibody is for its original immunogen, denatured modified DNA. The specificity of 5D11 was also tested against BPDE-I-dG, the monoadduct isolated from modified DNA, BPDE-Itetraols, the hydrolysis products of BPDE-I, and BPDE-II modified DNA. Figure 3 shows there is no crossreactivity with free tetraols while BPDE-I-dG has a 50% inhibition at 21,000 fmole compared to 19 fmole for denatured BPDE-I-DNA. The higher reactivity with DNA compared to monoadduct suggests that the antibody recognizes antigenic determinants in the surrounding DNA structure. When tested with BPDE-II-DNA, 50% inhibition was at 4400 fmole indicating that the antibody is sensitive to the stereochemistry of the BP chromophore.
This can be contrasted with antibody 8E11 which was generated against the monomeric adduct coupled with BSA. It has a lower sensitivity to BPDE-I-DNA (50% inhibition at 350 fmole) than 5D11 (50% inhibition at 19 fmole). (Fig. 4) . However, it has better reactivity against the monoadduct BPDE-1-dG (50% inhibition at 145fmole) than with DNA. In addition, it shows good cross-reactivity against BPDE-I tetraols (50% at 250 fmole). This suggests that the antibody recognizes mainly determinants present on the BP ring. It is specific for BPDE-I since it does not react with BPDE-II-DNA.
The sensitivity of antibodies 5D2, 4C2, and 1D7 for denatured BPDE-I-DNA is shown in Figure 5 . Antibody 5D2 is the most sensitive with a 50% inhibition at 17 fmole while the values for 4C2 and 1D7 are 160 and 370 fmole, respectively. Table 2 summarizes all the data on the specificity and sensitivity of the antibodies. The four antibodies generated from animals immunized with BPDE-I-DNA show their highest reactivity to DNA with a greater than 1000-fold difference in reactivity between DNA and monoadduct. The one antibody generated to the monoadduct, however, shows a near 2-fold higher reactivity with the monoadduct than the DNA. All are fairly specific for BPDE-I adducts showing much lower crossreactivity with BPDE-II-dG and BPDE-II-DNA. Two other carcinogen-modified DNAs were tested for antibody binding. Neither N-2-acetylaminofluorene or 1-aminopyrene modified DNA showed any cross-reactivity with any of the antibodies when tested at high concentrations.
The dependence of antibody reactivity on the secondary structure of the nucleic acids was shown by the difference in reactivity of antibody 5D11 to native and denatured BPDE-I-DNA. Studies with antibody 8E11 indicated that it reacts with a relatively similar sensitivity with the BPDE-1 chromophore whether it was free in solution (BPDE-I-tetraols), on dG or on DNA. However, when tested with BPDE-I-poly G, 50% inhibition was at 20,000 fmole. After treatment with NaOH to generate monoribonucleotides and neutralization the 50% inhibition dropped to 360 fmole. These studies indicate that the secondary structure of the nucleic acid can interfere with antibody binding quantitation of modification levels. and, therefore,
Testing of Human Samples
In a competitive ELISA it is possible to test a maximum of 50 ,g of DNA in a well. If 20% inhibition (about 5 fmole with antibody 5D11) is considered the lower limit of sensitivity in the assay, it is possible to quantitate levels of adducts in the range of 1 per 107 to 10' bases. This high level of sensitivity is especially important for quantitating DNA damage in human tissues, where the expected levels of DNA modification are likely to be extremely low. We are currently using the monoclonal antibodies described in this paper to continue studies on quantitating BP levels in human and animal samples (17, 21) . The use of monoclonal antibodies and further improvements in the sensitivity of the immunoassays will hopefully further facilitate human monitoring and provide a valuable tool in studies of human cancer causation. 
